Highlights•Human epidermal growth factor receptor 2 (HER2) alterations lead to poor
prognosis in non-small-cell lung cancer (NSCLC).•Identifying HER2 alterations is pivotal to …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

In non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2
(HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the …

Background Building on the success of targeted therapy in certain well-defined cancer
genotypes, three platform studies—NCI-MATCH, LUNG-MAP and The National Lung Matrix …

Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …

Multiple oncogenic molecular alterations have been discovered that serve as potential drug
targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological …

Antibody-drug conjugates (ADCs) represent a cornerstone in the treatment of many cancers
nowadays. ADCs fulfill their function by binding a target on tumor cell membrane to deliver a …

HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …

The oncogene ERBB2 encoding the receptor tyrosine-protein kinase erbB-2 (HER2) is
frequently overexpressed or amplified and occasionally mutated in a variety of human …